Insider Selling: Edwards Lifesciences Co. (NYSE:EW) VP Sells 2,570 Shares of Stock

Edwards Lifesciences Co. (NYSE:EW - Get Free Report) VP Donald E. Bobo, Jr. sold 2,570 shares of the business's stock in a transaction on Monday, June 2nd. The shares were sold at an average price of $77.40, for a total transaction of $198,918.00. Following the completion of the transaction, the vice president now directly owns 50,356 shares of the company's stock, valued at $3,897,554.40. This trade represents a 4.86% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Edwards Lifesciences Price Performance

Shares of NYSE EW traded down $0.06 during trading hours on Thursday, hitting $77.79. 130,753 shares of the stock were exchanged, compared to its average volume of 5,182,069. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.89 and a current ratio of 3.46. The company has a market cap of $45.63 billion, a PE ratio of 11.13, a price-to-earnings-growth ratio of 4.82 and a beta of 1.12. The company's fifty day simple moving average is $73.76 and its two-hundred day simple moving average is $72.64. Edwards Lifesciences Co. has a 1-year low of $58.93 and a 1-year high of $95.25.

Edwards Lifesciences (NYSE:EW - Get Free Report) last posted its quarterly earnings results on Wednesday, April 23rd. The medical research company reported $0.64 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.60 by $0.04. The business had revenue of $1.41 billion for the quarter, compared to analyst estimates of $1.40 billion. Edwards Lifesciences had a net margin of 72.93% and a return on equity of 19.40%. The firm's revenue for the quarter was up 6.2% on a year-over-year basis. During the same quarter last year, the business posted $0.66 EPS. On average, sell-side analysts predict that Edwards Lifesciences Co. will post 2.45 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of brokerages recently weighed in on EW. Wall Street Zen lowered shares of Edwards Lifesciences from a "buy" rating to a "hold" rating in a research note on Friday, May 16th. Wolfe Research downgraded shares of Edwards Lifesciences from a "hold" rating to a "strong sell" rating in a research note on Wednesday, February 12th. Barclays increased their price objective on shares of Edwards Lifesciences from $88.00 to $90.00 and gave the stock an "overweight" rating in a research note on Thursday, February 13th. Royal Bank of Canada restated an "outperform" rating and set a $85.00 price objective on shares of Edwards Lifesciences in a research note on Wednesday, February 12th. Finally, Truist Financial reduced their price objective on shares of Edwards Lifesciences from $78.00 to $75.00 and set a "hold" rating for the company in a research note on Friday, April 11th. One research analyst has rated the stock with a sell rating, fourteen have assigned a hold rating and eleven have issued a buy rating to the company's stock. According to data from MarketBeat, Edwards Lifesciences currently has an average rating of "Hold" and a consensus price target of $80.20.

Institutional Trading of Edwards Lifesciences

A number of hedge funds have recently added to or reduced their stakes in EW. Brighton Jones LLC bought a new position in shares of Edwards Lifesciences during the fourth quarter valued at $266,000. Strategic Blueprint LLC bought a new position in shares of Edwards Lifesciences during the fourth quarter valued at $203,000. Mediolanum International Funds Ltd raised its stake in shares of Edwards Lifesciences by 0.7% during the fourth quarter. Mediolanum International Funds Ltd now owns 54,340 shares of the medical research company's stock valued at $4,024,000 after acquiring an additional 354 shares during the last quarter. Caprock Group LLC bought a new position in shares of Edwards Lifesciences during the fourth quarter valued at $623,000. Finally, Heck Capital Advisors LLC bought a new position in shares of Edwards Lifesciences during the fourth quarter valued at $309,000. Institutional investors and hedge funds own 79.46% of the company's stock.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.